***TASK*** the task is to summarize an input biomedical literature in six sentences 
    ***INPUT*** the input is a biomedical literature 
    ***OUTPUT*** the output is the summary of an input biomedical literature in six sentences 
    ***DOCUMENTATION*** 
    ***EXAMPLES*** 
    Input: PURPOSE To evaluate the efficacy and safety of ixabepilone in patients with metastatic breast cancer ( MBC ) resistant to anthracycline , taxane , and capecitabine , in this multicenter , phase II study . PATIENTS AND METHODS Patients with measurable disease who had tumor progression while receiving prior anthracycline , taxane , and capecitabine were enrolled .  Ixabepilone 40 mg/m(2 ) monotherapy was administered as a 3-hour intravenous infusion on day 1 of a 21-day cycle . The primary end point was objective response rate ( ORR ) , assessed by an independent radiology facility ( IRF ) . RESULTS A total of 126 patients were treated and 113 were assessable for response . Patients were heavily pretreated : 88 % had received at least two lines of prior chemotherapy in the metastatic setting .  IRF-assessed ORR was 11.5 % ( 95 % CI , 6.3 % to 18.9 % ) for response-assessable patients . Investigator-assessed ORR for all treated patients was 18.3 % ( 95 % CI , 11.9 % to 26.1 % ) . Fifty percent of patients achieved stable disease ( SD ) ; 14.3 % achieved SD > or= 6 months . Median duration of response and progression-free survival were 5.7 and 3.1 months , respectively . Median overall survival was 8.6 months . Patients received a median of 4.0 treatment cycles ( range , one to 16 cycles ) , and 25 % of patients received > or= eight cycles . Grade 3/4 treatment-related events included peripheral sensory neuropathy ( 14 % ) , fatigue/asthenia ( 13 % ) , myalgia ( 8 % ) , and stomatitis/mucositis ( 6 % ) . Resolution of grade 3/4 peripheral sensory neuropathy occurred after a median period of 5.4 weeks . CONCLUSION Ixabepilone demonstrated clear activity and a manageable safety profile in patients with MBC resistant to anthracycline , taxane , and capecitabine . Responses were durable and notable in patients who had not previously responded to multiple prior therapies 
    Output:
    
Ixabepilone plus capecitabine has prolonged the median time to progression , increased overall survival and significantly increased response rates compared with capecitabine alone .
Adverse events observed with the combination arm were generally manageable and well tolerated with neutropenia and febrile neutropenia , and peripheral neuropathy , myalgia , diarrhea , stomatitis and h and -foot syndrome were easily controlled .
Ixabepilone plus capecitabine demonstrated clinical activity with an acceptable safety profile , which seems to be a valid option for patients with anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer